Fructose Stimulated De Novo Lipogenesis is Promoted by Inflammation
Overview
Authors
Affiliations
Benign hepatosteatosis, affected by lipid uptake, de novo lipogenesis and fatty acid (FA) oxidation, progresses to non-alcoholic steatohepatitis (NASH) on stress and inflammation. A key macronutrient proposed to increase hepatosteatosis and NASH risk is fructose. Excessive intake of fructose causes intestinal-barrier deterioration and endotoxaemia. However, how fructose triggers these alterations and their roles in hepatosteatosis and NASH pathogenesis remain unknown. Here we show, using mice, that microbiota-derived Toll-like receptor (TLR) agonists promote hepatosteatosis without affecting fructose-1-phosphate (F1P) and cytosolic acetyl-CoA. Activation of mucosal-regenerative gp130 signalling, administration of the YAP-induced matricellular protein CCN1 or expression of the antimicrobial peptide Reg3b (beta) peptide counteract fructose-induced barrier deterioration, which depends on endoplasmic-reticulum stress and subsequent endotoxaemia. Endotoxin engages TLR4 to trigger TNF production by liver macrophages, thereby inducing lipogenic enzymes that convert F1P and acetyl-CoA to FA in both mouse and human hepatocytes.
Relationship Between FODMAP Diet and Irritable Bowel Syndrome: A Mendelian Randomization Study.
Wang L, Cao W, Zheng Q, Li D, Hou Y, Chen S Food Sci Nutr. 2025; 13(2):e70037.
PMID: 39968214 PMC: 11833296. DOI: 10.1002/fsn3.70037.
Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis.
Takawy M, Abdelmalek M Curr Diab Rep. 2025; 25(1):23.
PMID: 39964660 DOI: 10.1007/s11892-025-01579-1.
Hyperuricemia-induced complications: dysfunctional macrophages serve as a potential bridge.
Gu W, Zhao J, Xu Y Front Immunol. 2025; 16:1512093.
PMID: 39935474 PMC: 11810932. DOI: 10.3389/fimmu.2025.1512093.
Unveiling the link between chronic inflammation and cancer.
Tripathi S, Sharma Y, Kumar D Metabol Open. 2025; 25:100347.
PMID: 39876904 PMC: 11772974. DOI: 10.1016/j.metop.2025.100347.
Potential therapeutic strategies for MASH: from preclinical to clinical development.
Xie Z, Li Y, Cheng L, Huang Y, Rao W, Shi H Life Metab. 2025; 3(5):loae029.
PMID: 39872142 PMC: 11749562. DOI: 10.1093/lifemeta/loae029.